NCT05429697View on ClinicalTrials.gov

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

January 8, 2025

Study Completion Date

June 8, 2026

Conditions
Biliary Tract Cancer
Interventions
DRUG

SMT-NK inj.+Pembrolizumab

"SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle."

DRUG

Pembrolizumab

Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Trial Locations (3)

10408

RECRUITING

National Cancer Center, Goyang-si

03722

RECRUITING

Severance Hospital, Seoul

06273

RECRUITING

Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

SMT bio Co., Ltd.

INDUSTRY